Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

10.1200/JCO.2010.30.1382

Fielding, 2007, Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study, Blood, 109, 944, 10.1182/blood-2006-05-018192

Tavernier, 2007, Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial, Leukemia, 21, 1907, 10.1038/sj.leu.2404824

10.1016/S1470-2045(12)70580-6

10.1200/JCO.2014.56.3247

10.1056/NEJMoa1407222

10.1126/scitranslmed.3008226

10.1016/S0140-6736(14)61403-3

10.1517/14712598.2015.1009888

10.1111/imr.12136

10.1172/JCI85309

10.1182/blood-2012-07-441030

Grupp, 2015, Durable remissions in children with relapsed/refractory all treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019), Blood, 126, 10.1182/blood.V126.23.681.681

10.1172/JCI45851

10.1002/pbc.20063

10.3343/kjlm.2007.27.4.253

10.1002/pbc.20782

10.1158/2159-8290.CD-15-1020

10.1111/his.12079

Del Giudice, 2004, The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes, Haematologica, 89, 303

Fromm, 2011, Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma, Cytometry B Clin Cytom, 80, 91, 10.1002/cyto.b.20561

10.1016/j.lfs.2014.10.013

10.1309/AJCPO4DS0GTLSOEI

10.3324/haematol.2008.000299

10.1182/blood-2004-03-0901

10.1053/j.seminhematol.2008.09.010

Muñoz, 2001, Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies, Haematologica, 86, 1261

Jordan, 2000, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells, Leukemia, 14, 1777, 10.1038/sj.leu.2401903

10.1080/104281090310001646031

10.1182/blood.V99.12.4634

10.3324/haematol.2014.111740

10.1007/s00262-004-0643-4

10.3109/10428194.2014.956316

10.1016/j.nucmedbio.2014.02.003

10.1093/protein/gzs040

10.1126/scitranslmed.aaa5693

Fan, 2015, AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells, J Hematol Oncol, 8, 10.1186/s13045-015-0109-5

10.1182/blood-2013-09-529537

10.1182/blood-2012-12-474056

Tettamanti, 2013, Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors, Immunol Lett, 155, 43, 10.1016/j.imlet.2013.09.013

10.1056/NEJMoa1215134

10.1182/blood-2011-04-346528

Harris, 2012, Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells, Nature, 486, 545, 10.1038/nature11098

10.1056/NEJMoa0811036

Chu, 2009, Mechanisms of resistance to FLT3 inhibitors, Drug Resist Updat, 12, 8, 10.1016/j.drup.2008.12.001

10.1182/blood-2010-12-326405

10.1126/science.1164266

10.1038/nm1253

10.3109/10428194.2012.754096

10.1111/j.1365-2141.2010.08300.x

10.1158/2326-6066.CIR-13-0008

Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat Biotechnol, 31, 71, 10.1038/nbt.2459

10.1038/mt.2013.185

10.1007/s10875-012-9689-9

10.1038/mt.2013.262

10.1126/scitranslmed.3006597

10.1158/2326-6066.CIR-15-0231

Luo, 2015, First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia, Blood, 126, 10.1182/blood.V126.23.3778.3778

Tasian, 2015, Efficient termination of CD123-redirected chimeric antigen receptor T cells for acute myeloid leukemia to mitigate toxicity, Blood, 126, 10.1182/blood.V126.23.565.565

10.1038/modpathol.3880556

10.1038/mt.2009.83

Imai, 2004, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, 18, 676, 10.1038/sj.leu.2403302

10.1038/leu.2015.52

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 10.1126/scitranslmed.3002842

10.1158/1078-0432.CCR-15-1527